Table 1

Demographic data

Variablen=274%
Median age, years (range)49 (24–82)
Diagnosis institution
 SNH13950.7
 NCI CC6122.3
 OSH7427
Treating institution
 SNH16861.3
 NCI CC10638.7
Race/ethnicity
 Non-Hispanic White2910.6
 Hispanic White16660.6
 African American3412.4
 Afro-Caribbean/Afro-Latina4215.3
 Other31.1
Language
 English11441.6
 Spanish14051.1
 Haitian Creole186.6
 Other/unknown20.8
Insurance status
 Private8229.9
 Medicare/Medicaid9936.1
 County charity care6423.4
 Self-pay2910.6
Stage*
 Group 1: IA1–IB211642.3
 Group 2: IB3–IVA14151.5
 Group 3: IVB165.8
Pre-treatment PET
 Yes19169.7
 No8330.3
Pre-treatment MRI pelvis
 Yes8430.7
 No19069.3
Pre-treatment EUA
 Yes11341.2
 No16158.8
First treatment received*
 Surgery10538.3
 Chemoradiation11040.1
 Systemic chemotherapy2910.6
 Clinical trial248.8
Recurrence
 Yes9735.4
 No17764.6
Moore
 024689.8
 12810.2
  • Moore criteria: performance status, pelvic disease, African-American ancestry, disease-free interval <1 year, and prior platinum exposure were assigned a score and tabulated as a total. Risk was assigned: low risk (0-1 factor), mid-risk (2-3 factors), & high risk (4 or 5 factors).

  • *Missing data points were excluded from analysis.

  • EUA, exam under anesthesia; MRI, magnetic resonance imaging; NCI CC, National Cancer Institute designated cancer center; OSH, outside institution; PET, positron emission tomography; SNH, safety net hospital.